Teva Pharma Announces Indication Extension Of Trisenox In EU - Quick Facts

(RTTNews) - Teva Pharmaceutical Industries Ltd., (TEVA) announced the company has obtained approval from the European Commission for an indication extension of Trisenox (arsenic trioxide). The indication extension is for newly diagnosed low to intermediate risk Acute Promyelocytic Leukemia in combination with retinoic acid.

Teva Pharma noted that this marks an important advancement in treatment for Acute Promyelocytic Leukemia patients in Europe, as it is the first time that a form of acute leukemia can be effectively treated with a regimen that is entirely chemotherapy-free. The decision by the European Commission grants marketing authorization for first line use of Trisenox in the 28 countries of the European Union.